Traws Pharma (TRAW) Stock: Buy, Sell, or Hold?
TRAW - Traws Pharma, Inc. Common Stock
$0.37
-0.01 (-2.47%)
▼
5d:
-9.03%
30d:
-27.18%
90d:
-24.87%
HOLD
LOW Confidence
Analysis Updated: Oct 21, 2026 12:00 AM ET
Earnings: Nov 12, 2026
20d
Get Alerted When TRAW Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: TRAW shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: TRAW shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: TRAW is currently trading at $0.37, which is considered oversold relative to its 30-day fair value range of $0.41 to $0.56.
Technical Outlook: Technically, TRAW is in a strong downtrend. The price is currently testing key support at $0.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TRAW scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.00 (+166.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, TRAW is in a strong downtrend. The price is currently testing key support at $0.36. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: TRAW scores 68/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $1.00 (+166.0%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.41 -
$0.56
Company Quality Score
54/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (68/100)
- BULLISH: Trading 166.0% below Wall St target ($1.00)
- CAUTION: Bottoming setup, but lagging the sector by 22% over 20 days — wait for relative strength
- CAUTION: 5-day price weakness (-9.0%) - monitor closely
Trading Range Analysis
30-Day Trading Range
$0.41 -
$0.56
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.36
Resistance Level
$0.47
Current Trend
Strong Downtrend
Technical data as of
Oct 22, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.20
Wall Street Target
$1.00
(+166.0%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: October 22, 2026 4:55 PM ET
Data refreshes hourly during market hours. Next update: 5:55 PM
Data refreshes hourly during market hours. Next update: 5:55 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is TRAW showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
VRTX
Vertex Pharmaceuticals I… |
STRONG BUY
32 analysts |
$571 | 49 HOLD |
|
ALNY
Alnylam Pharmaceuticals … |
STRONG BUY
30 analysts |
$369 | 50 HOLD |
|
ONC
BeiGene, Ltd. |
STRONG BUY
27 analysts |
$436 | 39 SELL |
|
ASND
Ascendis Pharma AS |
STRONG BUY
21 analysts |
$307 | 51 HOLD |
|
RYTM
Rhythm Pharmaceuticals I… |
STRONG BUY
18 analysts |
$144 | 70 BUY |